Doxil leverages the Enhanced Permeability and Retention (EPR) effect, a phenomenon where nanoparticles preferentially accumulate in tumor tissue due to its leaky vasculature and poor lymphatic drainage. By encapsulating doxorubicin in liposomes, Doxil can circulate longer in the bloodstream and deliver the drug directly to the tumor site, thus increasing the concentration of the drug at the target while reducing systemic toxicity.
